CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
May 14, 2024 08:30 ET
|
Centogene NV
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued...
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
September 01, 2023 08:00 ET
|
Centogene NV
Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of...